Company Overview More
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
CEO: Mack M.B.A., Anthony P.
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

VRPX Virpax Pharmaceuticals

5.350+0.650+13.83%
Close 09/27 17:13 ET
5.340-0.01-0.19%
Post Mkt Price 09/27 17:15 ET
High
5.470
Open
4.690
Turnover
21.78M
Low
4.690
Prev.Close
4.700
Volume
4.19M
Market Cap
62.68M
P/E(TTM)
Loss
52Wk High
36.000
Shares
11.72M
P/E
Loss
52Wk Low
3.700
H Mkt Cap
36.45M
Bid-Ask Ratio
-8.33%
Historical High
36.000
H Shares
6.81M
Vol. Ratio
1.63
Historical Low
3.700
Dividend TTM
--
Div Yield TTM
--
P/B
8.32
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
61.50%
Amplitude
16.60%
Avg Price
5.197
Min Trading Unit
1
Float Market Cap
36.45M
Bid-Ask Ratio
-8.33%
Historical High
36.000
Float
6.81M
Vol. Ratio
1.63
Historical Low
3.700
Dividend TTM
--
P/B
8.32
Dividend LFY
--
Turnover Ratio
61.50%
Amplitude
16.60%
Avg Price
5.197
Min Trading Unit
1
Price Forecast

Loading...

News